Pharmacy Benefit Manager (PBM)
A Pharmacy Benefit Manager (PBM) is a third-party administrator that sits at the center of the U.S. prescription drug supply chain, positioned between health insurers, employers, drug manufacturers, and pharmacies. PBMs perform a range of functions that determine how Americans access and pay for prescription medications: they design drug formularies (the lists of covered drugs), negotiate rebates with pharmaceutical manufacturers, contract with pharmacy networks, process prescription claims in real time, and administer mail-order and specialty pharmacy programs. For most insured Americans, a PBM operates silently and invisibly behind every prescription they fill — yet its pricing and formulary decisions directly determine what patients pay at the counter, which drugs appear on their plan’s covered list, and which pharmacy they are steered toward. More than 270 million Americans receive their prescription drug benefits through a PBM, making the industry one of the most consequential and least understood sectors in U.S. healthcare.
The business model of PBMs has become the subject of intense regulatory, legislative, and legal scrutiny heading into 2026. PBMs historically generated revenue through a combination of manufacturer rebates, spread pricing (billing plan sponsors more than they reimburse pharmacies and keeping the difference), administrative fees, and preferential steering of prescriptions to their own affiliated pharmacies. Critics — including the Federal Trade Commission (FTC), independent pharmacists, patient advocates, and a bipartisan coalition in Congress — argue that these revenue practices inflate drug list prices, harm independent pharmacies, and leave patients with higher out-of-pocket costs than necessary. In a landmark development, Congress enacted the Consolidated Appropriations Act of 2026 (CAA 2026) on February 3, 2026, representing the most comprehensive federal reform of PBM practices in U.S. history. With prescription drug spending projected to surpass $1 trillion for the first time in 2026, understanding the structure, scale, and transformation of the pharmacy benefit industry has never been more urgent.
Interesting US Pharmacy Benefit Facts 2026 — At a Glance
US Pharmacy Benefit Key Facts Dashboard — 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
💊 $1 TRILLION+ in US prescription drug spending projected for 2026
📈 $915 billion in drug spending in 2025 — up 12.7% YoY (ASHP)
🏢 3 PBMs process 80% of all US prescription claims (DCI, 2025)
👥 270+ million Americans covered by a PBM (NAIC report)
🔬 GLP-1 drugs = ~14% of all US prescription spending in 2025
🏥 Specialty drugs = 50%+ of total drug spend in 2025–2026
⚖️ CAA 2026 enacted February 3, 2026 — landmark PBM reform law
💸 $1.4 billion in PBM spread pricing profits (FTC, 2020–2022)
🏪 326 pharmacy storefronts closed in <10 weeks post Dec 2024
🎯 $2,000 Medicare Part D out-of-pocket cap effective January 2025
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Interesting Fact | Data Point | Source / Context |
|---|---|---|
| US prescription drug spending (2025) | $915 billion — up 12.7% from 2024 | ASHP Annual Drug Expenditures Report, April 2026 |
| US prescription drug spending (2026 projection) | Projected to exceed $1 trillion for the first time | ASHP Annual Drug Expenditures Report, April 2026 |
| 2025 drug spending growth rate | 12.7% — one of the fastest growth rates in two decades | ASHP / PharmExec, April 2026 |
| Top 2 drugs by spend (2025) | Tirzepatide & semaglutide (GLP-1s) — ~$60 billion each | ASHP, April 2026 |
| GLP-1 share of total US drug spending (2025) | ~14% of all US prescription drug spending | ASHP / PharmExec, April 2026 |
| GLP-1 share of all 2025 spending growth | GLP-1s drove ~one-third of all spending growth | ASHP Annual Drug Expenditures Report, April 2026 |
| Specialty drugs’ share of total spend | More than 50% of total drug spend in 2025–2026 | Mercer Government Drug Trend Report 2026 |
| Top 3 PBMs’ market share (claims, 2025) | 80% of all equivalent prescription claims | Drug Channels Institute (DCI) 2026 Economic Report |
| Americans covered by PBMs | 270+ million individuals | NAIC report cited in Market.us, April 2026 |
| PBM industry market size (US, 2026) | $638 billion (IBIS World) / $646.6 billion (Fortune Business Insights) | IBIS World 2026; Fortune Business Insights 2026 |
| PBM industry CAGR (2020–2025) | 5.6% compound annual growth rate | IBIS World United States PBM Industry Report 2026 |
| PBM-generated spread pricing profit | $1.4 billion in spread pricing profits (2020–2022, Big 3 PBMs) | FTC Second Interim Staff Report, January 2025 |
| PBM-affiliated pharmacy excess revenue | $7.3 billion in revenue above estimated acquisition costs (2017–2022) | FTC Second Interim Staff Report, January 2025 |
| Medicare Part D OOP cap (2025–2026) | $2,000/year (2025); adjusted to $2,100 in 2026 | IRA / CMS; IntuitionLabs 2026 |
| Independent pharmacy closures (10 weeks, early 2025) | 326 pharmacy storefronts, of which 237 independent, closed in fewer than 10 weeks after Dec 2024 | American Economic Liberties Project (AELP) / Drug Topics, 2025 |
| Rural independent pharmacy closures (2013–2022) | ~10% of independent retail pharmacies in rural America closed | FTC Staff Report on PBMs |
| Landmark reform law enacted | Consolidated Appropriations Act, 2026 — signed February 3, 2026 | Congress.gov; Mintz; KFF; AJMC, February 2026 |
| FTC settlement with Express Scripts | FTC secured landmark settlement in February 2026 | KFF / IntuitionLabs, February 2026 |
| 10 drugs with Medicare-negotiated prices | IRA-negotiated prices for 10 high-expenditure drugs took effect January 2026 | CMS / IntuitionLabs 2026 |
| Negotiated drug price discounts | 38%–79% off list prices for first 10 negotiated Medicare drugs | IntuitionLabs 2026 |
Data Sources: ASHP Annual Drug Expenditures Report (April 30, 2026); Drug Channels Institute 2026 Economic Report on US Pharmacies and Pharmacy Benefit Managers; FTC Second Interim Staff Report on PBMs (January 2025); KFF — What to Know About PBMs and Federal Efforts at Regulation (February 9, 2026); IBIS World US Pharmacy Benefit Management Industry Report 2026; Fortune Business Insights PBM Market Report 2026; American Economic Liberties Project (AELP) / Drug Topics (2025); Mintz — Congress Passes Landmark PBM Reform in 2026 Spending Bill (February 6, 2026)
The facts table above reveals a pharmacy benefit landscape in 2026 that is defined by two simultaneous and equally dramatic trends: explosive spending growth and unprecedented regulatory intervention. US prescription drug spending reached $915 billion in 2025 — a 12.7% increase in a single year, which ASHP described as one of the fastest growth rates in two decades — and is now on an inexorable path toward crossing $1 trillion in 2026 for the first time in American history. That milestone is being driven not primarily by higher drug prices but by a surge in the number of patients using high-cost medications, particularly GLP-1 weight-loss drugs that together consumed approximately $132 billion in spending and accounted for roughly one-third of all US prescription spending growth in 2025 alone. The scale of this shift is extraordinary: the GLP-1 class of drugs now represents ~14% of all US prescription drug spending, and the two highest-spending drugs — tirzepatide and semaglutide — each cost approximately $60 billion, more than double the third-highest drug.
The regulatory intervention side is equally historic. The FTC’s findings — that the Big 3 PBMs generated $1.4 billion in spread pricing profits and steered $7.3 billion in excess revenues to their own affiliated pharmacies over just a five-year period — provided the evidentiary foundation for the legislative action that followed. The 326 pharmacy closures in fewer than 10 weeks following the collapse of earlier reform efforts in December 2024 demonstrated the urgency of the problem in human terms: independent pharmacies cannot survive on reimbursements set below their acquisition costs. The Consolidated Appropriations Act of 2026, signed into law by President Trump on February 3, 2026, represents Congress’s answer — the most sweeping federal PBM reform in history, mandating 100% rebate pass-through, flat bona fide service fees, comprehensive transparency reporting, and any-willing pharmacy provisions beginning in 2028–2029.
PBM Market Size & Industry Growth 2026 | US Revenue Statistics
US PBM Industry Revenue Growth (Projected)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Year Market Size (US / Global) YoY Growth
─────────────────────────────────────────────────────
2020 ~$440B ████████████░░░░░░░░░░░░░░░░░░░░░
2021 ~$465B ████████████░░░░░░░░░░░░░░░░░░░░░
2022 ~$490B █████████████░░░░░░░░░░░░░░░░░░░░
2023 ~$530B █████████████░░░░░░░░░░░░░░░░░░░░
2024 $571B ██████████████░░░░░░░░░░░░░░░░░░░
2025 $609B ███████████████░░░░░░░░░░░░░░░░░░ +8.6%
2026 $647B ████████████████░░░░░░░░░░░░░░░░░ +6.2%
2034 $994B ████████████████████████░░░░░░░░░ (proj.)
CAGR 2025–2034: 5.5%–5.7%
US share of global PBM market (2024): 96.96%
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| PBM Market Metric | Data Point |
|---|---|
| US PBM industry market size (IBIS World, 2026) | $638.0 billion |
| Global PBM market size (2025) | $609.13 billion |
| Global PBM market size (2026 projection) | $646.61 billion |
| Global PBM market size (2024 actual) | $571.1 billion |
| Global PBM market size (2034 projection) | $994.2 billion |
| CAGR (2025–2034) | 5.5%–5.7% |
| CAGR (2020–2025, US industry) | 5.6% |
| Expected 2025 US PBM growth rate | 8.6% |
| US share of global PBM market (2024) | 96.96% |
| Number of PBM businesses in US | 87 businesses in the US PBM industry |
| Number of PBM companies serving individuals (NAIC) | 66 PBM companies serving 270+ million individuals |
| Key growth drivers (2026) | Specialty drug expansion, GLP-1 surge, AI-based formulary management, IRA Part D redesign |
| State regulatory tailwinds | California, Colorado, Arkansas “delinking” laws; rebate pass-through mandates across multiple states |
Data Sources: IBIS World Pharmacy Benefit Management in the US Industry Analysis 2026; Fortune Business Insights PBM Market Report 2026 (published with 2026 projections); Market.us Global PBM Market News, April 21, 2026; NAIC report
The US PBM industry’s market size of approximately $638–$647 billion in 2026 places it among the largest intermediary industries in the entire US economy — larger than the gross domestic product of most countries. The 96.96% US share of the global PBM market is a function of a uniquely American healthcare architecture: the multi-payer, employer-sponsored insurance model creates the demand for a complex intermediary layer between insurers, manufacturers, and pharmacies that does not exist at the same scale in countries with single-payer systems. With 87 PBM businesses operating in the United States but just three companies controlling 80% of all prescription claims, the industry is defined by extreme concentration at the top alongside a long tail of regional and specialty PBMs competing for the remaining share. The 8.6% growth rate projected for 2025 reflects the combined momentum of specialty drug expansion, the GLP-1 revolution, and new Medicare Part D dynamics driven by the Inflation Reduction Act.
The 5.5%–5.7% CAGR projected through 2034 suggests that even as the CAA 2026 reforms reshape how PBMs earn revenue — shifting from rebate-linked compensation to flat service fees — the overall market will continue to grow at a healthy pace. This is because PBMs’ core value proposition — adjudicating billions of prescription claims, managing pharmacy networks, and negotiating drug pricing — does not disappear under reform; it simply shifts to a different compensation structure. The real uncertainty in the growth projection lies in whether CAA 2026’s rebate pass-through and delinking mandates will meaningfully compress margins at the Big 3 PBMs or whether those companies will successfully offset lost rebate revenue through restructured administrative fees. Industry analysts at First Analysis note that the reform is already creating demand for a new ecosystem of transparency infrastructure, analytics platforms, and modern pharmacy benefit systems to manage the expanded reporting and compliance obligations that take effect beginning in 2028.
Big 3 PBM Market Share & Prescription Claims 2026
Top PBM Prescription Claim Volume (2025, DCI Estimates)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Express Scripts (Cigna)
████████████████████████████░░░░ 2.22 billion claims (+4.8% YoY)
CVS Caremark (CVS Health)
████████████████████████░░░░░░░░ 2nd place (volume declined 2nd yr)
OptumRx (UnitedHealth Group)
██████████████████████░░░░░░░░░░ 3rd place (growing)
All Other PBMs (20% combined)
████████░░░░░░░░░░░░░░░░░░░░░░░░ Independent PBMs gaining share
BIG 3 COMBINED: 80% of all US prescription claims
─────────────────────────────────────────────────────────────
Vertically integrated (own insurer + PBM): 5 of top 6 PBMs
Medicare Part D concentration (Big 3): >75% of the market
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| PBM Market Share Metric | Data Point | Source |
|---|---|---|
| Big 3 PBM combined claims share (2025) | 80% of all equivalent prescription claims | Drug Channels Institute (DCI) 2026 Economic Report |
| Express Scripts (Cigna) — 2025 claim volume | 2.22 billion equivalent prescription claims | DCI 2026 Economic Report (March 2026) |
| Express Scripts YoY growth (2024→2025) | +4.8% growth (from 2.12B in 2024 to 2.22B in 2025) | DCI 2026 Economic Report |
| Express Scripts ranking (2025) | #1 PBM by claim volume — 2nd consecutive year at top | Drug Channels / DCI, March 2026 |
| CVS Caremark (CVS Health) — 2025 trend | Claim volume declined for the second consecutive year | DCI 2026 Economic Report (March 2026) |
| OptumRx (UnitedHealth Group) — position | 3rd — maintaining market position | DCI 2026 Economic Report (March 2026) |
| Vertical integration — top 6 PBMs | 5 of the 6 largest PBMs are owned by organizations that also own a health insurer | Drug Channels Institute 2024–2026 |
| Medicare Part D — Big 3 market share | >75% of the Medicare Part D PBM market | PMC / JAMA published study 2025 |
| Independent PBMs trend | Gaining business from Big 3 at the margins | DCI 2026 Economic Report (March 2026) |
| Rebate aggregation illusion | Big 3’s rebate negotiation reach exceeds their 80% claims share due to rebate aggregators | DCI 2026 Economic Report (clarification note) |
| UnitedHealth Group / Optum Rx full rebate pass-through | Committed to full rebate pass-through beginning January 2026 | AJMC / CVS Health / UHG statements |
| CVS Caremark rebate pass-through | Has offered rebate pass-through options since 2019 | AJMC, February 2026 |
Data Sources: Drug Channels Institute (DCI) 2026 Economic Report on US Pharmacies and Pharmacy Benefit Managers (March 30, 2026); Drug Channels Blog — “The Top Pharmacy Benefit Managers of 2025” (March 30, 2026); PMC / JAMA study on PBM market concentration; AJMC — PBM Reforms Signed Into Law (February 2026)
The three-company concentration at the top of the US PBM market is, as the Drug Channels Institute describes it, “extraordinarily high — and remarkably stable.” For years running, CVS Caremark, Express Scripts, and OptumRx have collectively processed approximately 80% of all US equivalent prescription claims, and that share has barely shifted despite years of regulatory pressure, political debate, and competitive noise. The most notable development within the Big 3 in 2025 is the internal reshuffling: Express Scripts extended its lead at the top for the second consecutive year, growing claims by 4.8% to 2.22 billion in 2025, while CVS Caremark’s volume declined for the second year running — a trajectory linked in part to the loss of the Elevance Health contract, which reduced CVS Caremark’s revenues and managed claims as Elevance built its own specialty and mail pharmacy capabilities. Independent PBMs continued gaining business from these three companies at the margins, suggesting that while concentration remains extreme, it is not impervious to competitive pressure.
The vertical integration dimension is perhaps the most structurally significant feature of the 2026 PBM landscape. Five of the six largest PBMs in the US are now owned by organizations that also own a health insurer — meaning the same corporate entity designs the insurance benefit, manages the formulary, processes the prescription claims, and in many cases owns the specialty pharmacy that dispenses the drug. This integration is precisely what the CAA 2026 and the FTC’s ongoing scrutiny are targeting: the concern is that these vertically integrated entities can steer prescriptions to their own affiliated pharmacies, favor drugs with higher rebates on formularies, and disadvantage independent pharmacies — all within a single corporate decision structure. The commitment by OptumRx to full rebate pass-through beginning January 2026 and by Cigna/Express Scripts to eliminate the rebate-retention model signals that the industry is adapting its business models in advance of the formal mandates.
US Prescription Drug Spending Statistics 2026 | GLP-1s, Specialty & Growth Drivers
US Prescription Drug Spending by Setting — Growth Rates 2025 (ASHP)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Total Overall Spending: $915B ████████████████████████████████ +12.7%
Clinic Drug Expenditures: ██████████████████████████████░░ +19.0%
Hospital Drug Spend: ████████████████░░░░░░░░░░░░░░░░ +9.6%
Drug class breakdown of 2025 US spending:
─────────────────────────────────────────────────────────────────
GLP-1 drugs (tirzepatide + semaglutide): ~$132B (~14% of all spend)
─ Tirzepatide: ~$60B ████████████████████░░░░░░░░░░░░░░░░░░░░
─ Semaglutide: ~$60B ████████████████████░░░░░░░░░░░░░░░░░░░░
─ Apixaban (#3):~$29B ██████████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Specialty drugs: >50% of total US drug spend (2025–2026)
Brand drugs: 80% of all drug spending (vs. 80% generic Rxs)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| US Drug Spending Metric | Data Point | Source |
|---|---|---|
| Total US prescription drug spending (2025) | $915 billion | ASHP Annual Drug Expenditures Report, April 30, 2026 |
| YoY spending growth (2025 vs 2024) | +12.7% — one of fastest in 20 years | ASHP / PharmExec, April 2026 |
| Total US drug spending projection (2026) | >$1 trillion | ASHP Annual Drug Expenditures Report, April 30, 2026 |
| 2026 overall spending growth forecast | 10%–12% | ASHP, April 2026 |
| 2026 clinic drug spending growth forecast | 14%–16% | ASHP, April 2026 |
| 2026 hospital drug spending growth forecast | 4%–6% | ASHP, April 2026 |
| Tirzepatide spend (2025, #1 drug) | ~$60 billion | ASHP April 2026 |
| Semaglutide spend (2025, #2 drug) | ~$60 billion | ASHP April 2026 |
| Apixaban spend (2025, #3 drug) | ~$29 billion — less than half of #1 and #2 | ASHP April 2026 |
| GLP-1 combined spend (2025) | ~$132 billion — driving ~one-third of all 2025 growth | ASHP April 2026 |
| GLP-1 share of total US drug spending | ~14% of all US prescription drug spending | ASHP / PharmExec, April 2026 |
| Clinic expenditure growth (2025) | +19% | ASHP April 2026 (fastest of any care setting) |
| Hospital drug spend growth (2025) | +9.6% driven by oncology & immunotherapy | ASHP April 2026 |
| Specialty drug share of total spending | >50% of all drug spending in 2025–2026 | Mercer Government Drug Trend Report 2026 |
| Brand drugs’ share of spending | ~80% of prescription drug spending despite ~80% of prescriptions being generic | ASPE HHS / ASHP |
| CMS projected avg annual retail Rx growth (2023–2032) | 6.0% compound annual growth | CMS National Health Expenditure Projections |
| Traditional drug trend 2025–2026 (Medicaid) | 8.0%–9.0% | Mercer Government Drug Trend Report 2026 |
| Specialty drug trend 2025–2026 (Medicaid) | 6.5%–10.5% | Mercer Government Drug Trend Report 2026 |
| Consumer out-of-pocket share (2023 actual) | $58.2 billion = 13% of net outpatient drug expenditures | Drug Channels Institute / CMS NHE Data, 2025 |
| Consumer OOP share projection (2033) | Expected to decline to 11% of net spending | CMS National Health Expenditure Projections 2024–2033 |
Data Sources: ASHP Annual Drug Expenditures Report and Projections for 2026 (April 30, 2026 / PRNewswire); PharmExec — “US Prescription Drug Spending Set to Exceed $1 Trillion” (April 30, 2026); Mercer Government Drug Trend & Pipeline 2025 Report; ASPE HHS — Trends in Prescription Drug Spending; Drug Channels Institute / CMS NHE Data; CMS National Health Expenditure Projections 2024–2033
The milestone of US prescription drug spending crossing $1 trillion in 2026 is one of the most significant benchmarks in the history of American healthcare finance. To place it in context: this is a spending level that in 2023 would have been considered a mid-decade projection, not an imminent reality. The ASHP’s lead author Eric Tichy framed the dynamic plainly: GLP-1 drugs at $132 billion accounted for nearly one-third of all 2025 spending growth, and the market is still in the steep early adoption phase. Tirzepatide and semaglutide each cost approximately $60 billion annually — more than double the third-highest drug and more than most individual disease categories spent in total just five years ago. The growth is being driven primarily by utilization increases (more patients using more medications) rather than price increases, which fundamentally changes how the policy and payer community needs to think about it: cutting prices alone will not solve a spending trajectory driven by expanding patient populations.
The brand drug spending paradox remains one of the most counterintuitive facts in US pharmacy economics: approximately 80% of all prescriptions filled in the US are for generic drugs, yet brand name drugs account for approximately 80% of all prescription drug spending. This concentration means that a relatively tiny slice of the drug pipeline — primarily specialty, biologic, and branded medications — determines the vast majority of total cost trends. Specialty drugs alone now exceed 50% of total US drug spending while representing a small fraction of total prescription volume. This gap is exactly what PBM formulary management is designed to address — but the FTC’s finding that PBMs were systematically steering high-profit specialty prescriptions to their own affiliated pharmacies rather than lower-cost alternatives suggests the formulary management function has not always been deployed in the plan sponsor’s or patient’s interest.
PBM Reform 2026 | Consolidated Appropriations Act Key Provisions
CAA 2026 — PBM Reform Timeline & Key Provisions
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
February 3, 2026 CAA 2026 signed into law by President Trump
─────────────────────────────────────────────────────────────────
NOW (2026): Transparency & reporting requirements take effect
DOL proposed rule on ERISA self-insured plans
FTC settlement with Express Scripts finalized
2028: Flat "bona fide service fees" replace rebate-linked
compensation in Medicare Part D
100% rebate pass-through to employer health plans
Semiannual plan-level reporting REQUIRED
Annual audit rights for plan sponsors REQUIRED
$10,000/day fines for information failures
$100,000 fines for knowingly false submissions
2029 (Jan 1): Any-Willing Pharmacy provision — all pharmacies
meeting standard terms can join Part D networks
"Essential retail pharmacy" protections for rural areas
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| CAA 2026 Reform Provision | Detail | Effective Date / Source |
|---|---|---|
| Signed into law | President Trump signed H.R. 7148 / CAA 2026 on February 3, 2026 | Mintz / KFF / AJMC, February 2026 |
| Delinked PBM compensation (Part D) | PBMs must receive flat, bona fide service fees — no longer linked to drug price or rebate size | Beginning 2028 (Part D plan year) |
| 100% Rebate Pass-Through (employer plans) | PBMs must pass 100% of rebates, fees, and other remuneration to group health plans | 2028–2029 |
| 100% Rebate Pass-Through (Part D) | PDP/MA-PD sponsors must enforce full rebate pass-through | Beginning 2028 plan year |
| Semiannual plan-level reporting | PBMs must report: gross/net drug spending, rebates, spread pricing, formulary structure, affiliated pharmacy steerage | 2028–2029 (quarterly on request) |
| Annual audit rights | Plan sponsors can request comprehensive audit at least once per year | 2028–2029 |
| Enforcement penalties | $10,000 per day for information failures; $100,000 for knowingly false submissions | 2028–2029 |
| Any-Willing Pharmacy (Part D) | Part D sponsors must allow any pharmacy meeting standard contract terms to participate | January 1, 2029 |
| “Essential retail pharmacy” designation | New designation protecting access in rural and underserved markets | January 1, 2029 (HHS defines by April 2028) |
| Broad PBM definition in law | Explicitly includes rebate aggregators, GPOs, utilization management entities — not just traditional PBMs | Effective in statute, February 2026 |
| Medicare PBM reform implementation | CMS updates standard PDP/MA-PD contracts with uniform reporting formats | CMS schedule, 2026–2028 |
| CBO estimated 10-year savings | $2.12 billion net deficit reduction (2026–2035) | CBO / KFF, February 2026 |
| DOL proposed rule (ERISA plans) | Requires PBMs contracting with self-insured ERISA plans to disclose compensation, rebates, spread pricing | Proposed January 30, 2026; comments closed March 31, 2026 |
| FTC-Express Scripts settlement (Feb 2026) | Required elimination of spread pricing, delinking PBM compensation from drug prices, cost-plus reimbursement for independent pharmacies (≤3 locations) | February 2026 |
Data Sources: Mintz — Congress Passes Landmark PBM Reform in 2026 Spending Bill (February 6, 2026); KFF — What to Know About PBMs and Federal Efforts at Regulation (February 9, 2026); AJMC — PBM Reforms Signed Into Law (February 4, 2026); Buchanan Ingersoll & Rooney — Sweeping PBM Reforms Arrive (February 12, 2026); Akin Gump — PBM Reform Picks Up Pace (February 4, 2026); First Analysis — What PBM Federal Reform Means for the Rx Value Chain (April 2026)
The Consolidated Appropriations Act of 2026 is the legislative culmination of more than a decade of bipartisan, bicameral effort to regulate PBM business practices — and it is far-reaching in ways that will take years to fully manifest. The most structurally significant provision is the delinking of PBM compensation from drug prices and rebate amounts in Medicare Part D, replacing the existing model with flat bona fide service fees that reflect the fair-market value of services actually performed. This change, effective with the 2028 Part D plan year, removes the financial incentive for PBMs to favor high-list-price drugs — because under the old model, a PBM’s rebate revenue grew as list prices grew, creating a perverse incentive to tolerate or even encourage high list prices that generate larger rebate percentages. The 100% rebate pass-through requirement for employer group health plans is equally significant: it means the cost savings that PBMs negotiate from drug manufacturers must flow to the plan sponsor, and ultimately to plan participants, rather than being retained by the PBM.
The enforcement teeth embedded in the CAA 2026 — $10,000 per day for information failures and $100,000 for knowingly false submissions — represent a meaningful escalation from previous reform efforts that relied primarily on disclosure without penalties. Combined with the annual audit rights granted to plan sponsors, these provisions fundamentally alter the information asymmetry that has characterized the PBM industry for decades. Plan sponsors will, for the first time, have legally enforceable rights to access drug-level pricing data, rebate amounts, spread pricing arrangements, and formulary placement rationales in a standardized, reportable format. The Any-Willing Pharmacy provision effective January 1, 2029 addresses a different dimension of the problem: the network exclusion of independent pharmacies that has contributed to the closure of hundreds of community pharmacies. By requiring Part D networks to accept any pharmacy meeting standard contract terms, the law opens the door for independent and rural pharmacies that have been systematically excluded from PBM networks despite being the only accessible option for patients in their communities.
FTC Actions Against PBMs 2025–2026 | Key Enforcement Statistics
FTC PBM Enforcement Timeline & Key Findings (2024–2026)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
July 2024: FTC releases preliminary study — Big 3 control 79% of
commercial Rx claims; anticompetitive practices alleged
Oct 2024: FTC files lawsuit against Big 3 PBMs for rigging
insulin/diabetes drug supply chain
Jan 2025: FTC Second Interim Report:
► Big 3 marked up >50% of specialty generics by
hundreds or thousands of percent
► $7.3B excess revenue to PBM-affiliated pharmacies
► $1.4B spread pricing profits
► Affiliated pharmacies got 72% of high-markup scripts
(vs 44% of overall specialty scripts)
Mar 2025: Trump fires 2 FTC Democratic commissioners → quorum lost
Jul 2025: New FTC commissioners appointed → quorum restored
Aug 2025: FTC stay on PBM case lifted; proceedings resume
Feb 2026: FTC secures landmark settlement with Express Scripts
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| FTC Enforcement Data Point | Statistic / Finding | Source |
|---|---|---|
| Big 3 PBMs’ commercial claims share (FTC) | 79% of commercial prescription claims (FTC 2024 preliminary study) | FTC PBM Preliminary Staff Report, July 2024 |
| Specialty generic drugs analyzed (FTC 2nd report) | 51 specialty generic drugs studied across 2017–2022 | FTC Second Interim Staff Report, January 2025 |
| PBM markup frequency | Big 3 marked up >50% of specialty generic drugs studied by hundreds or thousands of percent (2020–2022) | FTC Second Interim Staff Report, January 2025 |
| PBM-affiliated pharmacy excess revenue | $7.3 billion in revenue above estimated acquisition costs (2017–2022) | FTC Second Interim Staff Report, January 2025 |
| Big 3 spread pricing profit | $1.4 billion in spread pricing profits | FTC Second Interim Staff Report, January 2025 |
| Spread pricing commercial share | 97% of spread pricing profit came from commercial prescriptions at unaffiliated pharmacies | FTC Second Interim Report; HIV-HCV Watch, 2025 |
| Prescription steering to affiliated pharmacies | PBM-affiliated pharmacies filled 72% of high-markup specialty scripts (vs 44% of overall specialty volume) | FTC Second Interim Staff Report, January 2025 |
| FTC lawsuit (Oct 2024) | Filed against Caremark, Express Scripts, OptumRx for allegedly rigging the insulin/diabetes drug supply chain | FTC / Frier Levitt, 2025 |
| FTC quorum disruption | Trump fired 2 Democratic FTC commissioners in March 2025 — case temporarily stalled | IntuitionLabs 2026 |
| FTC proceedings resumed | New commissioners appointed July 2025; stay lifted August 2025 | IntuitionLabs 2026 |
| Express Scripts FTC settlement (Feb 2026) | Required: (1) elimination of spread pricing; (2) delinking PBM compensation from drug prices; (3) cost-plus reimbursement for independent pharmacies (≤3 locations) | KFF / IntuitionLabs, February 2026 |
| Allegation in Express Scripts case | Express Scripts allegedly inflated insulin costs by pushing manufacturers to compete for formulary placement based on rebate size rather than net price | KFF, February 9, 2026 |
Data Sources: FTC Second Interim Staff Report on Pharmacy Benefit Managers (January 14, 2025); FTC Preliminary Study / First Staff Report (July 2024); Hall Render — FTC Releases Second Interim Staff Report on PBMs (January 29, 2025); IntuitionLabs — PBMs Explained: Role in Drug Pricing & Healthcare System (March 2026); KFF — What to Know About PBMs (February 9, 2026); HIV-HCV Watch, 2025
The FTC’s investigation of the Big 3 PBMs produced some of the most damning quantitative evidence of systemic anti-competitive behavior in recent US healthcare enforcement history. The Second Interim Staff Report of January 2025 — covering 51 specialty generic drugs across a five-year period — documented with drug-level detail how PBM-affiliated pharmacies were paid dramatically higher reimbursements than independent pharmacies for the same drugs, and how high-markup prescriptions were systematically steered to those affiliated pharmacies. The 72% affiliated pharmacy share of prescriptions for the most heavily marked-up drugs (compared to 44% of overall specialty volume) is not a coincidence of patient preference — it is the mathematical fingerprint of deliberate formulary and network design. The $7.3 billion in excess revenue to PBM-affiliated pharmacies and $1.4 billion in spread pricing profits are the financial outcomes of that design, ultimately borne by plan sponsors, employers, and patients in the form of higher premiums, higher cost-sharing, and reduced drug access.
The FTC-Express Scripts settlement of February 2026 — secured after the extraordinary sequence of FTC quorum disruption and restoration that characterized 2025 — established important precedents for what reform looks like in practice. The requirement of cost-plus reimbursement for independent pharmacies with three or fewer locations is particularly meaningful: it directly targets the mechanism by which spread pricing has driven small community pharmacies into insolvency by reimbursing them below their acquisition cost for the same drugs that PBM-affiliated pharmacies receive premium reimbursements to dispense. Combined with the CAA 2026’s statutory prohibition on spread pricing in Medicare Part D beginning 2028, and the DOL’s proposed rule extending transparency requirements to ERISA self-insured plans, the 2026 enforcement and legislative actions represent the most coordinated federal assault on PBM pricing opacity since the industry became a dominant force in US healthcare.
State PBM Reform Statistics 2026 | Patchwork Regulation & Key Laws
State PBM Reform Activity — 2025–2026 Snapshot
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
States with active PBM reform laws (2025–2026): 30+ states
State AGs urging federal action (April 2025): 39 of 50 AGs
─────────────────────────────────────────────────────────────
Key state actions:
West Virginia: 100% rebate pass-through mandate since 2021
→ 52% reduction in 2025 small-group rate increases
Arkansas: First state to BAN PBM ownership of pharmacies (2025)
→ Preliminary injunction halted enforcement (July 2025)
Colorado: "Delinking" law — PBM compensation not tied to prices
California: "Delinking" law — PBM compensation not tied to prices
Massachusetts: Comprehensive PBM licensing & transparency requirements
Utah: HB 257 (May 2025) — rebates used solely for enrollees
Idaho: Annual PBM registration with DOI; $300 fee; full disclosure
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| State PBM Reform Data Point | Statistic / Provision | Source |
|---|---|---|
| State AGs demanding federal PBM reform (April 2025) | 39 state attorneys general signed joint letter urging Congressional action | First Analysis, April 2026; ALEC, February 2026 |
| West Virginia — HB 2263 (2021) impact | 100% rebate pass-through mandate; 2024 review found it cut average 2025 small-group insurance rate increase by 52% | ALEC Article — US House Passes PBM Reforms, February 2026 |
| Arkansas — Act 624 (HB 1150, 2025) | First state to ban PBMs from owning or operating retail or mail-order pharmacies (vertical integration ban) | ALEC, February 2026 |
| Arkansas — legal challenge | Federal judge issued preliminary injunction on July 28, 2025 citing Commerce Clause and ERISA concerns | ALEC, February 2026 |
| Colorado & California | Enacted “delinking” laws prohibiting PBM compensation tied to drug prices | First Analysis, April 2026 |
| Massachusetts | Enacted comprehensive PBM licensing and transparency requirements | First Analysis, April 2026 |
| Utah — HB 257 (effective May 7, 2025) | Requires health plans to use rebates solely for enrollee benefits (reducing OOP costs, premiums, or benefit enhancement) | ALEC, February 2026 |
| Idaho — annual PBM registration | All PBMs register with the Idaho Department of Insurance annually; $300 fee; must disclose costs, fees, and rebates | ALEC, February 2026 |
| West Virginia — anti-discrimination rules | PBMs prohibited from reimbursing affiliated pharmacies at higher rates than independents | ALEC, February 2026 |
| State spread pricing bans (Medicaid) | Several states have banned spread pricing in Medicaid, requiring transparent pass-through pricing | AJMC 5 Policy Goals Driving PBM Reform, March 2026 |
| ERISA pre-emption challenge | Many state reforms face potential ERISA pre-emption for self-insured employer plans — major limiting factor | AJMC / ALEC, 2026 |
| Federal-state coordination (CAA 2026) | CAA 2026 provides new federal baseline, reducing reliance on state-by-state patchwork for ERISA plans | Mintz / KFF, February 2026 |
Data Sources: American Legislative Exchange Council (ALEC) — US House Passes PBM Reforms: Where Are We Now? (February 2026); First Analysis — What PBM Federal Reform Means for the Rx Value Chain (April 2026); AJMC — 5 Policy Goals Driving PBM Reform Efforts (March 2026); Buchanan Ingersoll & Rooney (February 12, 2026)
The state-level PBM reform landscape heading into 2026 is best described as an aggressive but legally constrained patchwork. More than 30 states have enacted some form of PBM oversight legislation, and 39 of 50 state attorneys general had signed a joint letter by April 2025 demanding federal action — a level of bipartisan state consensus that is rare in US healthcare policy. The outcomes of state reform have been instructive. West Virginia’s 2021 100% rebate pass-through mandate is the most compelling real-world proof point: a 2024 review by the state’s Insurance Commissioner found that the law had reduced the average 2025 small-group insurance rate increase by 52% — a tangible, dollar-quantifiable consumer benefit from a single transparency and pass-through provision. This kind of evidence was instrumental in building the political case for the federal legislation that followed.
The Arkansas vertical integration ban — the first of its kind nationally, prohibiting PBMs from owning or operating retail or mail-order pharmacies — represents the most aggressive state reform attempted, and the fact that it was immediately challenged and halted by a federal preliminary injunction illuminates the central legal tension in state PBM reform: ERISA pre-emption. Because the Employee Retirement Income Security Act governs self-insured employer health plans at the federal level, state laws that regulate how those plans’ pharmacy benefits are administered face constant legal challenge. This is precisely why federal action through the CAA 2026 is so consequential — it establishes a national baseline for ERISA plans that does not face pre-emption challenges, and it covers the commercially insured population that has been most difficult for states to reach through their own laws.
Medicare Part D Pharmacy Benefit Statistics 2026 | IRA Reforms & Drug Pricing
Medicare Part D Key Benefit Changes — IRA & CAA 2026 Impact
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
2023: $35/month insulin cost-sharing cap (IRA) takes effect
2025: $2,000 annual OOP cap for Part D beneficiaries (IRA)
2026: $2,100 adjusted OOP cap
Negotiated prices for 10 drugs take effect (38%–79% off list)
CBO deficit reduction from IRA drug provisions kicks in
2028: Flat bona fide service fees replace rebate compensation (CAA)
100% rebate pass-through mandatory for Part D plans (CAA)
2029: Any-Willing Pharmacy provision takes effect (CAA)
Medicare Part D — Big 3 PBM market share:
─────────────────────────────────────────────────────────────
Big 3 PBMs: >75% of Medicare Part D prescription market
Medicare share of
national drug spend (2021): 32% (CMS data)
2024 Medicare drug spending growth: Highest rate in 10+ years
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Medicare Part D Pharmacy Benefit Data Point | Statistic | Source |
|---|---|---|
| Medicare Part D OOP cap (2025) | $2,000 per year maximum out-of-pocket drug costs | IRA / CMS |
| Medicare Part D OOP cap (2026) | $2,100 (adjusted from 2025 level) | IntuitionLabs 2026 |
| Medicare-negotiated drug prices — effective date | January 2026 — negotiated prices for first 10 high-expenditure drugs took effect | CMS / IntuitionLabs 2026 |
| Negotiated drug price discounts (IRA) | 38%–79% off list prices for the first 10 negotiated drugs | IntuitionLabs 2026 |
| Medicare insulin cost-sharing cap | $35 per month (effective 2023) | KFF / CMS, IRA |
| Medicare share of national drug spending (2021) | 32% of national drug spending — 2nd largest payer after private insurance | KFF Health System Tracker |
| Medicare drug spending growth (2024) | Highest rate of growth in over 10 years | Drug Channels / CMS NHE Data, February 2026 |
| IRA — OOP spending growth impact | Slowed OOP growth from 2.5% in 2024 to 0.6% in 2025 | Drug Channels / CMS NHE Projections |
| Big 3 PBM share of Medicare Part D market | >75% | PMC / JAMA study on PBM market concentration 2025 |
| Medicare enrollment with marketplace drug coverage | 22.4 million individuals had marketplace coverage in 2025 | Drug Channels, February 2026 |
| IRA OOP cap effect on utilization | Expected to increase utilization as cost barriers fall — increasing payer and system costs | Peterson-KFF Health System Tracker; ASHP |
| Medicare Part D IRA 10-year budget impact | CMS actuaries expect OOP provisions to plateau consumer out-of-pocket drug spending through next decade | CMS / Peterson-KFF |
| CAA 2026 — CBO Part D savings | $444 million reduction over 10 years from delinking PBM compensation in Part D | CBO / KFF, February 2026 |
| CAA 2026 — CBO employer plan savings | $1.865 billion reduction over 10 years from PBM oversight on employer plans | CBO / KFF, February 2026 |
| CAA 2026 — total deficit reduction (CBO) | $2.12 billion net over 10 years | CBO / KFF, February 2026 |
Data Sources: KFF — What to Know About PBMs and Federal Efforts at Regulation (February 9, 2026); Peterson-KFF Health System Tracker — Trends in Prescription Drug Spending; Drug Channels — Latest CMS Data Reveal Six Trends Reshaping US Drug Spending (February 2026); CMS National Health Expenditure Projections 2024–2033; IntuitionLabs — PBMs Explained (March 2026); PMC / JAMA study on PBM market concentration
Medicare Part D is the single most consequential payer segment in the US pharmacy benefit ecosystem, both because of its sheer size — covering 32% of national drug spending — and because it is the primary legislative and regulatory testing ground for PBM reform. The convergence of the IRA’s $2,000 out-of-pocket cap (effective 2025, adjusted to $2,100 for 2026), the January 2026 launch of negotiated drug prices for 10 high-expenditure drugs at discounts of 38%–79% off list price, and the CAA 2026’s Part D PBM reforms makes 2026 arguably the most consequential year in Medicare pharmacy benefit history since the program’s launch in 2006. The OOP cap alone had already slowed Medicare beneficiary out-of-pocket drug spending growth from 2.5% in 2024 to just 0.6% in 2025 — a dramatic deceleration that meaningfully improves financial security for seniors on fixed incomes but simultaneously increases utilization, shifting costs from patients to payers.
The $2.12 billion in net federal deficit reduction estimated by CBO from the CAA 2026’s PBM provisions is modest relative to the scale of the PBM industry — and that modesty is deliberate. The CBO’s estimate of $1.865 billion in savings from employer plan PBM oversight reflects the mechanism: when insurers have more information about PBM operations through mandated transparency, that information advantage leads to better contract negotiations and lower prescription costs, which in turn reduces premiums charged in the group health insurance market. It is a savings model built on information correction rather than direct price control. Critics of the reform argue this is insufficient given the $1.4 billion in spread pricing profits and $7.3 billion in affiliated pharmacy excess revenue documented by the FTC over just a portion of the time period. Proponents argue it is a structural first step that, combined with the enforcement penalties and audit rights, creates the compliance infrastructure for more consequential savings over time.
Independent Pharmacy Statistics 2026 | Closures, Access & PBM Impact
Independent Pharmacy Viability — Key Data Points 2025–2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Closures linked to PBM reimbursement pressures (early 2025):
──────────────────────────────────────────────────────────
Total closures in <10 weeks (post Dec 2024): 326 storefronts
Of which independent pharmacies: 237 (73%)
Rural independent closures (2013–2022): ~10% of all rural
independent Rx
Why pharmacies are closing:
─────────────────────────────────────────────────────────────
✖ PBM reimbursements below acquisition cost for specialty generics
✖ Mandatory steering to PBM-affiliated pharmacies
✖ High-profit scripts funneled to affiliated pharmacies (72% vs 44%)
✖ Network exclusion without clinical justification
✖ Abusive audit practices and clawbacks
CAA 2026 remedies:
─────────────────────────────────────────────────────────────
✔ Any-Willing Pharmacy (2029) opens Part D networks
✔ Cost-plus reimbursement for independent pharmacies <4 locations
(from FTC-Express Scripts settlement, Feb 2026)
✔ Spread pricing prohibited in Part D (2028)
✔ "Essential retail pharmacy" rural access designation (2029)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Independent Pharmacy Statistic | Data Point |
|---|---|
| Pharmacy closures — post Dec 2024 (10 weeks) | 326 pharmacy storefronts closed |
| Of which independent pharmacies | 237 independent pharmacies — 73% of closures |
| Rural independent pharmacy closures (2013–2022) | ~10% of all independent retail pharmacies in rural America closed |
| Root cause cited by AELP | Big 3 PBMs “abusing market power” — reimbursements below cost without Congressional intervention |
| FTC finding — high-markup steering | Affiliated pharmacies received 72% of high-markup specialty prescriptions (vs 44% of all specialty volume) |
| FTC finding — spread pricing target | 97% of spread pricing profit came from commercial prescriptions at unaffiliated (independent) pharmacies |
| Independent pharmacy reimbursement | Reimbursed at lower rates than affiliated pharmacies for same drugs on nearly every specialty generic drug studied |
| FTC-Express Scripts settlement remedy | Cost-plus reimbursement for independent pharmacies with 3 or fewer locations |
| Any-Willing Pharmacy (CAA 2026) | Any pharmacy meeting standard terms can join Part D networks starting January 1, 2029 |
| “Essential retail pharmacy” designation | New designation protects access in rural and underserved markets |
| West Virginia — rebate pass-through impact on pharmacies | Prohibitions on reimbursing affiliated pharmacies at higher rates than independents |
| Arkansas vertical integration ban (status) | Law passed; preliminary injunction halted enforcement as of July 2025 |
Data Sources: American Economic Liberties Project (AELP) / Drug Topics — Over 300 Pharmacy Closures (2025); FTC Second Interim Staff Report on PBMs (January 2025); FTC PBM Staff Report (FTC.gov); IntuitionLabs — PBMs Explained (March 2026); Buchanan Ingersoll & Rooney — Sweeping PBM Reforms Arrive (February 12, 2026); ALEC — US House Passes PBM Reforms (February 2026)
The 326 pharmacy closures in fewer than 10 weeks following the collapse of earlier PBM reform efforts in the December 2024 Congressional spending package is the most visceral statistical illustration of what insufficient oversight of PBM reimbursement practices costs in human terms. The 237 independent pharmacies that closed in that brief window — equivalent to multiple closures every single day — did not fail because of poor business management or lack of patient demand. They closed because their PBM-set reimbursement rates fell below the acquisition cost of the drugs they were required to dispense, leaving no viable path to financial sustainability. This is the operational consequence of the FTC’s finding that PBMs engaged in spread pricing and affiliate preference at the expense of independent pharmacy networks: the spread pricing profits documented in the FTC report are not abstract financial transfers between institutions; they represent reimbursement dollars extracted from independent pharmacies that could not absorb further cuts.
The geographic dimension of these closures compounds the harm. When an independent pharmacy closes in a dense urban market, patients typically have multiple alternative options within a reasonable distance. When an independent pharmacy closes in a rural county — where, according to the FTC, approximately 10% of all rural independent pharmacies closed between 2013 and 2022 — it frequently creates a pharmacy desert where patients with chronic conditions, limited transportation, and no mail-order access face genuine barriers to medication adherence. The CAA 2026’s “essential retail pharmacy” designation and the Any-Willing Pharmacy provision effective 2029 are designed precisely for these communities. The FTC-Express Scripts settlement’s cost-plus reimbursement requirement for independent pharmacies with three or fewer locations addresses the same problem through enforcement rather than legislation. Together, these 2026 actions represent the most comprehensive attempt to stabilize the independent pharmacy sector in US history — but with implementation dates of 2028–2029, the intervening period remains a critical survival window for thousands of remaining community pharmacies.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
